key: cord-1048755-40nlp9xw
authors: Pang, A. P.; Higgins-Chen, A. T.; Comite, F.; Raica, I.; Arboleda, C.; Mendez, T.; Schotsaert, M.; Dwaraka, V.; Smith, R.; Levine, M. E.; Ndhlovu, L. C.; Corley, M. J.
title: Longitudinal study of DNA methylation and epigenetic clocks prior to and following test-confirmed COVID-19 and mRNA vaccination
date: 2021-12-05
journal: nan
DOI: 10.1101/2021.12.01.21266670
sha: 5d15f825498498654f36f6f6322a5c1715807c44
doc_id: 1048755
cord_uid: 40nlp9xw

The host epigenetic landscape is rapidly changed during SARS-CoV-2 infection and evidence suggests that severe COVID-19 is associated with durable scars to the epigenome. Specifically, aberrant DNA methylation changes in immune cells and alterations to epigenetic clocks in blood relate to severe COVID-19. However, a longitudinal assessment of DNA methylation states and epigenetic clocks in blood from healthy individuals prior to and following test-confirmed non-hospitalized COVID-19 has not been performed. Moreover, the impact of mRNA COVID-19 vaccines upon the host epigenome remains understudied. Here, we first examined DNA methylation states in blood of 21 participants prior to and following test confirmed COVID-19 diagnosis at a median timeframe of 8.35 weeks. 261 CpGs were identified as differentially methylated following COVID-19 diagnosis in blood at an FDR adjusted P value <0.05. These CpGs were enriched in gene body and northern and southern shelf regions of genes involved in metabolic pathways. Integrative analysis revealed overlap among genes identified in transcriptional SARS-CoV-2 infection datasets. Principal component-based epigenetic clock estimates of PhenoAge and GrimAge significantly increased in people over 50 following infection by an average of 2.1 and 0.84 years. In contrast, PCPhenoAge significantly decreased in people under 50 following infection by an average of 2.06 years. This observed divergence in epigenetic clocks following COVID-19 was related to age and immune cell-type compositional changes in CD4+ T cells, B cells, granulocytes, plasmablasts, exhausted T cells, and naive T cells. Complementary longitudinal epigenetic clock analyses of 36 participants prior to and following Pfizer and Moderna mRNA-based COVID-19 vaccination revealed vaccination significantly reduced principal component-based Horvath epigenetic clock estimates in people over 50 by an average of 3.91 years for those that received Moderna. This reduction in epigenetic clock estimates was significantly related to chronological age and immune cell-type compositional changes in B cells and plasmablasts pre- and post-vaccination. These findings suggest the potential utility of epigenetic clocks as a biomarker of COVID-19 vaccine responses. Future research will need to unravel the significance and durability of short-term changes in epigenetic age related to COVID-19 exposure and mRNA vaccination.

In this study, we first examined whether alterations to DNA methylation states, blood immune 96 cell type composition, and epigenetic clocks occurred in peripheral blood following COVID-19 using 97 a longitudinal study design of 21 healthy participants prior to and following test-confirmed COVID-98 19. Next, we also evaluated longitudinal DNA methylation states, blood immune cell type 99 composition, and epigenetic clocks of 36 healthy participants prior to and following complete two-100 dose mRNA-based COVID-19 vaccination. 101 102 2

Results 103

following test-confirmed COVID-19 infection. 105 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.01.21266670 doi: medRxiv preprint Table 1 presents the baseline (pre-COVID-19) characteristics of study participants prior to 106 COVID-19 diagnosis. Participants were healthy (n=14M, 7F) and ranged in chronological age from 107 18 to 73 years (Median = 46 years). Genome-wide DNA methylation was assayed from blood 108 biospecimens of all participants at baseline and post-COVID-19 using the Illumina MethylationEPIC 109 platform (Pidsley et al., 2016) . Baseline DNA methylation for participants was obtained at a median and ranged out to a maximum of 6 months after diagnosis. 116

To identify differentially methylated loci in blood related to COVID-19, we utilized a 118 longitudinal study design that included genome-wide DNA methylation data generated from 21 119 participants prior to (pre-COVID-19) and following COVID-19 diagnosis (post-COVID-19) 120 ( Fig.1a) . Our repeated measures analysis of DNA methylation at pre-and post-COVID-19 timepoints 121 revealed 756 differentially methylated loci significant at FDR (Benjamini-Hochberg) adjusted P < 122 0.05 that were not significantly biased to a specific chromosomal location (Fig.1b, Supplementary  123 Dataset 1). 57.8% of the COVID-19 related DML were increases in DNA methylation states (hyper-124 methylation) at the post-COVID-19 compared to pre-timepoint for participants. Next, we examined 125 whether these COVID-19 related DML in blood were enriched in specific genomic contexts and 126 found a significant enrichment in gene body (Odds Ratio= 1.2 ; P = 0.005) and northern (Odds 127 Ratio= 1.7 ; P = 0.0004) and southern (Odds Ratio= 1.8 ; P = 0.0001) shelf regions located adjacent 128

to CpG island shore regions compared to the expected distribution of methylation sites assayed 129 transcribed genes of the digestive system (sigmoid colon, q value = 8.42e-8; duodenum smooth 154 muscle, q value = 5.06e-8; rectal mucosa, q value = 3.19e-7; duodenum mucosa, q value = 3.19e-7), 155 placenta (q value = 6.21e-06), spleen (q value = 1.25e-05, brain (anterior caudate, q value= 1.32e-05; 156 hippocampus, q value= 2.13e-05), liver (q value = 3.92e-05), and lung (q value = 9.22e-05) 157 (Supplementary Dataset 2) . These data support the notion of COVID-19 impacting the epigenetic 158 landscape as a multisystem disorder involving both immune cells and nonimmune cells in disease 159 pathogenesis. 160

Among the top Δβ-value methylation changes comparing pre-and post-COVID-19 timepoints, 161 we observed two differentially methylated loci (cg02037503 and cg23712970) in a gene promoter 162 transcription start site regulatory region of the apoptotic chromatin condensation inducer 1 (ACIN1) 163 gene Supplementary Figure S2 that decreased in DNA methylation following COVID-19 by 164 approximately 15% for both CpG sites (Fig.1d,e) . This gene codes a nuclear protein that induces 165 apoptotic chromatin condensation after activation by caspase-3 (Sahara et al., 1999) , which we 166 previously reported was increased in red blood cells of hospitalized COVID-19 participants 167 (Plassmeyer et al., 2021) . We also observed differential methylation at cg10846936 related to the 168 caspase recruitment domain family member 14 (CARD14) gene that is involved in activating nuclear 169 factor-kappa-B involved in immune inflammation. Participants' methylation levels at this loci 170 increased comparing pre-and post-COVID-19 timepoints from a mean of 44.47% to 53.44% (Fig.1f) Figure S3 . 177 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. timepoints. Since the human immune system undergoes dramatic aging-related changes, we stratified 192 our analysis into two groups based on those under or over 50 years of age. We observed no 193 significant differences in the inferred proportion of CD8+ T cells following COVID-19 for those 194 under and over 50 years of age (Fig.2a) . Participants under 50 years of age showed significant 195 increases in the percentage of CD4+ T cells in blood following COVID-19 (Fig.2b) . In contrast, in 196 those over 50 years of age we observed a significant decrease in the percentage of CD4+ T cells in 197 blood following COVID-19 (Fig.2b) , reflecting COVID-19 reports of lymphopenia. Additionally, we 198 observed significant decreases in the percentage of B cells in those over 50 years of age (Fig.2d) . In 199 contrast, we observed shifts in decreasing plasmablasts percentage (Fig.2g ) and increasing CD4+ 200 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.01.21266670 doi: medRxiv preprint Naïve T cells were observed in those under 50 years of age following COVID-19 (Fig.2j) . Innate 201 immune NK and monocytes cell proportions did not significantly change following COVID-19 202 (Fig.2c,e) . We also did not observe significant differences in granulocytes, exhausted CD8+ T cells, 203 and CD8+ naïve T cells (Fig.2f,h,i) . Together, these findings suggest age-related COVID-19 shifts in 204 specific immune cell types occur in healthy individuals. 205

We utilized the inferred cell type proportional changes following COVID-19 to examine 206 relationships with age and the DNA methylation change pre-vs post-COVID-19 for ten of the top 207 differentially methylated loci we had identified. This correlative analysis showed that chronological 208 age was significantly associated with the percent change in DNA methylation for 9/10 DML, 209 suggesting the signal of change for those DNA methylation sites related to age and potential 210 plasticity loss (Fig.3) . Moreover, chronological age was significantly associated with the inferred cell 211 type proportional changes following COVID-19 for CD4+ T cells, plasmablasts, and CD4+ naïve T 212 cells adding further support to our observed age-related COVID-19 shifts in specific immune cell 213 types observations (Fig.3) . Notably, we observed that shifts in inferred immune cell type proportions 214 following COVID-19 significantly related to the extent of DNA methylation level changes for all of 215 the DML we examined suggesting the COVID-19 DNA methylation signature to be substantially 216 influenced by cell-type shifts (Fig.3) . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.01.21266670 doi: medRxiv preprint infection overlapped with COVID-19-related genes transcriptionally altered during SARS-CoV-2 224 infection utilizing the Enrichr COVID-19 gene set online tool (Kuleshov et al., 2016) . This analysis 225 revealed significant overlap with genes differentially expressed in SARS-CoV-2 animal models 226 (Rhesus macaques blood, P = 0.017; mouse heart, P = 0.018; mouse spleen, P = 0.027; and hamster 227 blood, P = 0.027), COVID-19 human biospecimens (late stage infection blood, P = 0.027; human 228 cornea, P = 0.032), and in vitro infection models (Calu3, P = 0.030) ( Table 2) (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.01.21266670 doi: medRxiv preprint measurements of the same sample to deviate up to 9 years (Higgins-Chen et al., 2021b). To mitigate 248 the impacts of these unreliable epigenetic clock estimates, we applied a novel principal-component 249 version of epigenetic clocks that permits a more reliable estimate for longitudinal studies (Higgins-250 Chen et al., 2021b). Next, we applied the principal-component epigenetic clocks algorithm based on 251 78,464 CpGs to the dataset to obtain PC-based epigenetic clock estimates and PC-based residuals after 252 regressing PC-age predicted by the algorithm over chronological age for participants prior to and 253 following COVID-19. Since age is a well-known risk factor for COVID-19 severity and our sample 254 set contained participants that ranged in chronological age from 18 to 73 years, we stratified our 255 longitudinal analysis of epigenetic clocks into two groups: people under 50 and people over 50 years 256 of age. Application of our novel principal component-based computational solution to optimize the 257 aging signal from epigenetic clocks and minimize noise revealed no significant differences in 258 epigenetic age based on the PCHorvath1, PCHorvath 2, and PCHannum epigenetic clocks for both 259 groups following COVID-19 ( Fig.4a-c) . Additionally, PCDNAmTL was not significantly altered 260 following COVID-19 (Fig.4d ). We observed that the PCPhenoAge clock was significantly increased 261 in those over 50 years of age following COVID-19 by an average of 2.1 years (Fig.4e,h) . In contrast 262 to the observations for those over 50 years of age, PCPhenoAge was significantly decreased in those 263 under 50 years of age following COVID-19 by an average of 2.06 years (Fig.4g ). Chronological age 264 significantly related to the extent of pre-vs post-COVID-19 epigenetic age increase in PCPhenoAge 265 ( Fig.4i) . Moreover, we observed that PCGrimAge, a predictor of lifespan in unit of years was 266 significantly increased in people over 50 years of age following COVID-19 by an average of 0.84 years 267 ( Fig.4f,k) . Chronological age significantly related to the extent of pre-vs post-COVID-19 epigenetic 268 age increase in PCGrimAge (Fig.4l) . PCGrimAge was not significantly impacted in those under 50 269 years of age (Fig.4j) . 270 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.01.21266670 doi: medRxiv preprint

We hypothesized that the COVID-19 associated change in PCPhenoAge and PCGrimAge was 271 related to immune cell type compositional changes. Indeed, we observed that the increase in the 272 PCPhenoAge clock estimate for participants following COVID-19 was significantly related to the 273 magnitude of changes in the percent of CD4 T cells, B cells, Granulocytes, plasmablasts, exhausted T 274 cells, CD8 naïve T cells, and CD4 naïve T cells (Fig.5) . We did not observe significant relationships 275 between the increase in PCPhenoAge and CD8T cells, NK cells, and monocytes ( 

To complement our pre-and post-COVID-19 exposure dataset, we sought to examine the 291 impact of mRNA COVID-19 vaccination upon epigenetic clocks by obtaining DNA methylation 292 profiles from blood of participants prior to and following mRNA COVID-19 vaccination. We 293 examined 36 individuals (n=21 Females; n=15 Males) ranging in age from 22 to 69 years old that 294 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.01.21266670 doi: medRxiv preprint received either the Moderna (n=13) or Pfizer (n=23) mRNA vaccine. The median time since the 295 second mRNA vaccine dose received by participants and DNA methylation data obtained for the 296 post-vaccination timepoint was 57.9 days. We calculated principal-component epigenetic clock 297 estimates and observed that PCHorvath1 and PCHorvath2 epigenetic age estimates were significantly 298 decreased following complete mRNA vaccination comparing pre-and post-vaccination timepoints 299 for all 36 participants by an average of 1.03 years and 1.58 years (Fig.6a,b) . Exploratory analyses 300 stratified by vaccine brand suggested that those over 50 years of age that received Moderna mRNA 301 vaccination significantly reduced epigenetic age estimates based on PCHorvath1 by an average 2.75 302 years and PCHorvath2 by an average 3.91 years following complete vaccination (Fig.7a,b) . In 303 contrast, we observed no significant differences in epigenetic age estimates for people under 50 that 304 received Moderna and for both those under and over 50 years of age that received Pfizer 305 ( Fig.7a,b,g,h) . Whether these stratified results relate to Moderna vaccine containing a higher dose 306 (100 micrograms) compared to Pfizer (30 micrograms) will need further examination. There was no 307 significant difference in time from last dose and when DNA methylation data was obtained post-308 vaccination between vaccine brands (Supplementary Figure S6) , suggesting time was not a 309 confounding factor for vaccine differences in epigenetic age reduction in those over 50 years of age. 310

In correlative analyses for all participants receiving an mRNA vaccine, we observed the extent of 311 decreasing epigenetic age based on the PCHorvath1 and PCHorvath2 clocks and increasing 312

PCDNAmTL significantly related to increasing chronological age (Fig.7m,n,q) . We did not observe 313 any significant differences from mRNA vaccination upon the PCHannum, PCPhenoAge, and PC 314 DNAmTL (Fig.7c ,d,e,i,j,k) and delta epigenetic age changes for PCHannum, PCPhenoAge, and PC 315

GrimAge were not significantly related to chronological age (Fig.7o,p,r) . 316

Next, we examined whether the decrease in PCHorvath1 and PCHorvath2 following mRNA 317 vaccination related to immune cell type compositional changes and/or DNA methylation inferred 318 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.01.21266670 doi: medRxiv preprint telomere length since previous data suggested telomere length related to influenza vaccine responses 319 (Najarro et al., 2015) . The delta change in PCHorvath1 following mRNA vaccination significantly 320 associated with delta change in PCDNAmTL and plasmablasts cell type percentage following 321 complete two dose mRNA vaccination (Fig.8) . The delta change in PCHorvath2 following mRNA 322 vaccination significantly associated with delta change in PCDNAmTL, B cell, granulocytes, and 323 plasmablasts following complete two dose mRNA vaccination (Fig.8) . Notably, we did not observe 324 any significant relationships between the time elapsed from when participants received their second 325 mRNA dose and post mRNA vaccine DNA methylation data was obtained and delta changes in all 326 epigenetic clock estimates and cell type compositional changes following mRNA vaccination (Fig.8) . 327

epigenetic clocks. 329

We tested whether artificial short-term in vitro exposure to SARS-CoV-2 virus (0.1 MOI) 330 impacted PC-based epigenetic clocks in human peripheral mononuclear cells. We exposed viable 331 PBMC's from two uninfected donors (Donor 1, under 50 years of age; Donor 2: over 50 years of age) 332 to a passage 4 stock of SARS-CoV-2 (0.1 MOI) in vitro for 60 hrs and compared DNA methylation 333 levels to mock uninfected. We did not observe evidence of SARS-CoV-2 replication in PBMCs after 334 60 hrs as assessed by nucleocapsid flow cytometry assessments. PC-based epigenetic estimates of 335 difference in epigenetic age comparing mock and SARS-CoV-2 exposed PBMC revealed changes 336 less than 1 year for PCHorvath1, PCHorvath2, and PCHannum clocks (Supplementary Figure S7) . 337

Notably, we observed divergent donor-dependent impacts from addition of monophosphoryl lipid A 338 (MPLA) stimulation, a TLR4 agonist, for 1 hr to 60hr SARS-CoV-2 exposed PBMC's for all PC-339 based clocks (Supplementary Figure S7) . As a comparator dataset, we generated DNA methylation 340 data from mock and SARS-CoV-2 infected Calu-3 cells for 96 hours and observed epigenetic age did 341 not increase for PC-based epigenetic clock comparing mock and infected cells. 342 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.01.21266670 doi: medRxiv preprint vaccination to impact epigenetic aging in the immune system. Future research will need to examine 368 whether COVID-19 and mRNA vaccine-related changes to epigenetic age are biologically 369 meaningful. It is important to note that although epigenetic age robustly predicts age-related 370 morbidity and mortality in cross-sectional studies ( COVID-19 exposure were due to cell type compositional changes. Notably, we also observed the 390 differentially methylated CpGs associated with COVID-19 were enriched in transcriptional gene sets 391 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.01.21266670 doi: medRxiv preprint more robust if multiple clocks predicting the same phenotype show the same relationship to COVID-417

A plausible interpretation of the PCPhenoAge/PCGrimAge results after infection is an age-419 related signal of both immunosenescence and inflammaging. Once the immune system is activated 420 in younger individuals by SARS-CoV-2 infection, they look younger by the epigenetic clock due to a 421 robust activation of the immune response that reflects younger individuals (not that they are actually 422 becoming younger). In older individuals, activation of non-specific inflammatory pathways after 423 SARS-CoV-2 infection appears to increase epigenetic age because of the activation of pathways that 424 overlap/are similar to inflammaging. An alternative interpretation for divergence in epigenetic age 425 based on age during SARS-CoV-2 infection might involve the biological process of hormesis: 426 moderate stressors can improve health by causing a compensatory response (Epel, 2020) . COVID-19 427 might serve as a hormetic stress in non-hospitalized younger individuals, while it serves as a toxic 428 stressor in older adults or any severe case. 429

Aging drives immunosenescence with implications for a decline in adaptive immunity 430 resulting in reduced vaccine responses and vaccine durability in older adults. The age-related decline 431 in immune function including reduced thymic output of naïve T cells and dampened B cell 432 generation has notably led to decreased vaccine efficacy in older individuals (Soiza et al., 2021) . 433

Indeed, building evidence for COVID-19 indicates a declined humoral and cellular immune response 434 in older individuals (Collier et al., 2021; Levin et al., 2021 ). Yet, failure to achieve a protected or 435 durable response after vaccination is poorly understood despite occurring commonly among many 436 elderly individuals. Our epigenetic clock data following mRNA COVID-19 vaccination revealed an 437 age-related decrease in epigenetic age following vaccination. Our findings also revealed that the 438 change in epigenetic age following vaccination was specifically related to immune-cell type 439 compositional changes in the percentage of B cells, plasmablasts, and granulocytes. These findings 440 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. Using standard epigenetic clock estimates, we observed variation up to 9 years in participants pre-459 and post-timepoint samples epigenetic age estimates for all clocks that lead to non-significant results. 460

While the application of PC-based epigenetic clocks pulled out a biological signal suggesting that 461 mild/moderate COVID-19 from SARS-CoV-2 infection and mRNA vaccination impacted epigenetic 462 clocks, the biological mechanisms that influence detrimental or beneficial changes in epigenetic 463 clocks remains unclear. Ongoing research is deconstructing dissimilar epigenetic clocks and may 464 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. of 21 participants provides a discovery dataset for examining the short-term impacts of COVID-19 488 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.01.21266670 doi: medRxiv preprint upon the host immune cell epigenome and impact on epigenetic clock estimates. Our longitudinal 489 COVID-19 DNA methylation dataset consisted of healthy participants that ranged across the lifespan 490 from 18 to 73 years of age. Moreover, the collection of DNA methylation data following test-confirmed 491 COVID-19 exposure occurred within a short-term time frame of a 6-month window and occurred early 492 during the COVID-19 pandemic reflecting infection with a less evolved, less contagious, and 493 potentially less severe SARS-CoV-2 virus than recent variants such as the Delta variant. Hence, our 494 findings are limited by these potential factors. These longitudinal findings need to be confirmed in a 495 larger sample size, across diverse regions and genotypes, among individuals across the lifespan, in 496 people infected with emerging SARS-CoV-2 variants, and across COVID-19 severities including those 497 individuals that recover and suffer from long-lasting symptoms termed post-COVID. 498

Despite the strengths of this longitudinal epigenetic study, there are several limitations. First, 499 our longitudinal study design only included two time points to examine changes related to COVID-500 19 and mRNA vaccination comparing baseline and a short-term follow-up assessment of DNA 501 methylation. future studies will need to study a larger sample size and determine whether these age-502 related divergent changes to epigenetic clocks are durable following COVID-19 and potentially relate 503 to those with long-COVID-19 syndrome. Additionally, there was variation in the time following 504 confirmed COVID-19 or mRNA COVID-19 vaccination for when the post sample assay for DNA 505 methylation was completed. Yet, given the complete lack of longitudinal DNA methylation studies of 506 COVID-19 and mRNA COVID-19 vaccination we provide discovery findings that are compelling 507 regarding specific DNA methylation changes and epigenetic clocks that warrant further investigation. 508

Future studies that have serial blood collection of participants throughout the course of mRNA-509 vaccination and even following booster shots will be extremely valuable for epigenetic clock 510

investigations. Recent technological advancements based on Tagmentation-based Indexing of 511

Methylation Sequencing (TIME-Seq) have scaled and reduced the cost of epigenetic age predictions 512 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.01.21266670 doi: medRxiv preprint permitting methodology for a more comprehensive study follow-up to our findings (Griffin et al., 513 2021) . We also acknowledge the limited clinical data for participants and that the SARS-CoV-2 514 infection DNA methylation dataset may be relevant to a early genetic lineage not reflecting emerging 515 variants being monitored nor variants of concern such as Delta (B.1.617.2) . 516 517 3

Methods 518

Deidentified DNA methylation data was generated by TruDiagnostic as part of a retrospective non-520 randomized study to assess the effects of SARS- COVID-19 methylation data to post-COVID-19 methylation data. Genes related to differentially 548 methylated loci were utilized for a COVID-19 gene set analyses from the Enrichr web tool (Kuleshov 549 et al., 2016) . 550 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Tables 639 Table 1 640

Post-COVID-19

Age ( (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.01.21266670 doi: medRxiv preprint

Heterologous SARS-CoV-2 Booster Vaccinations -Preliminary Report

Efficacy and 741 Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Blood 743 DNA methylation and COVID-19 outcomes

Quantification of the pace of biological aging in humans through a blood test, the 746 DunedinPoAm DNA methylation algorithm

Quantification of the pace of biological aging in humans through a blood test: the 749

Quantification of biological aging in young adults

Longitudinal 754 Multi-omics Analyses Identify Responses of Megakaryocytes, Erythroid Cells, and 755 Plasmablasts as Hallmarks of Severe COVID-19

757 CARD11 and CARD14 Are Novel Caspase Recruitment Domain (CARD)/Membrane-758 associated Guanylate Kinase (MAGUK) Family Members that Interact with

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed 765 participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Evaluation 768 of microarray-based DNA methylation measurement using technical replicates

An Epigenetic Clock Measures Accelerated 771 Aging in Treated HIV Infection

773 eFORGE v2.0: updated analysis of cell type-specific signal in epigenomic data

Epigenome-wide association study of COVID-19 severity with respiratory failure

Longitudinal 779 personal DNA methylome dynamics in a human with a chronic condition

Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2

Genome-wide DNA methylation profiling of peripheral blood reveals an epigenetic signature 786 associated with severe COVID-19

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 789 Vaccine for Covid-19

The geroscience agenda: Toxic stress, hormetic stress, and the rate of aging

Epigenetic 793 Clocks Are Not Accelerated in COVID-19 Patients

Responders and non-responders to influenza vaccination: A DNA methylation approach on 797 blood cells

Epigenetics of host-pathogen 799 interactions: the road ahead and the road behind

Ultra-801 cheap and scalable epigenetic age predictions with TIME-Seq. bioRxiv

Genome-wide 804 methylation profiles reveal quantitative views of human aging rates

Aging biomarkers and the brain

A computational solution for bolstering reliability of epigenetic clocks: Implications for 809 clinical trials and longitudinal tracking. bioRxiv

An epigenetic predictor of death captures multi-modal measures of brain health

Epigenetic measures of ageing predict the prevalence and incidence of leading 816 causes of death and disease burden

DNA methylation age of human tissues and cell types

HIV-1 Infection Accelerates Age According to the Epigenetic 819 Clock

Epigenetic 821 clock for skin and blood cells applied to Hutchinson Gilford Progeria Syndrome and ex vivo 822 studies

DNA methylation-based biomarkers and the epigenetic clock theory 824 of ageing

DNA methylation arrays as surrogate measures of cell mixture distribution

Mild 829 SARS-CoV-2 infection modifies DNA methylation of peripheral blood mononuclear cells 830 from COVID-19 convalescents

The COVID-19 Gene and Drug Set Library

Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic 836 Acids Res

COVID-838 19 severity is predicted by earlier evidence of accelerated aging

Waning 841 Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

An 844 epigenetic biomarker of aging for lifespan and healthspan

Underlying features of 846 epigenetic aging clocks in vivo and in vitro

The correlation of methylation levels measured using Illumina 450K and EPIC BeadChips in 849 blood samples

DNA methylation 851 GrimAge strongly predicts lifespan and healthspan

Evidence for Biological Age Acceleration and Telomere Shortening in COVID-19 Survivors

Evidence 856 for biological age acceleration and telomere shortening in covid-19 survivors

DNA methylation as a 859 transcriptional regulator of the immune system

Why does COVID-19 861 disproportionately affect older people?

Telomere Length as an 863 Indicator of the Robustness of B-and T-Cell Response to Influenza in Older Adults

Effectiveness of heterologous ChAdOx1 866 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in 867 Sweden: A nationwide cohort study

A 869 systematic review of biological, social and environmental factors associated with epigenetic 870 clock acceleration

Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome 873 DNA methylation profiling

Caspases and therapeutic potential of caspase inhibitors in moderate-severe SARS CoV2 876 infection and long COVID

Safety 878 and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Immunogenicity and efficacy of heterologous ChadOx1/BNT162b2 vaccination

Hyperglycemia in acute COVID-19 is characterized by insulin resistance and adipose tissue 884 infectivity by SARS-CoV-2

The 886 spatial landscape of lung pathology during COVID-19 progression

Acinus is a 889 caspase-3-activated protein required for apoptotic chromatin condensation

Epigenetic Landscape during Coronavirus Infection

Cellular immunity predominates over humoral immunity after homologous and heterologous 895 mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

Efficacy and safety of COVID-19 vaccines in 901 older people

Patterns of Reliability: Assessing the Reproducibility and Integrity of DNA 904 Methylation Measurement

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated 907 health system in the USA: a retrospective cohort study

ChAMP: updated 910 methylation analysis pipeline for Illumina BeadChips

SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses

A single-cell atlas of the peripheral immune response in patients with severe COVID-916 19

The single-cell 918 epigenomic and transcriptional landscape of immunity to influenza vaccination

Correlation of 921 an epigenetic mitotic clock with cancer risk

Epigenetic scars of CD8+ T cell exhaustion persist after cure of chronic infection in 924 humans

EpiDISH web server: 926 Epigenetic Dissection of Intra-Sample-Heterogeneity with online GUI

An epigenome-wide DNA 929 methylation study of patients with COVID-19

SeSAMe: reducing artifactual 931 detection of DNA methylation by Infinium BeadChips in genomic deletions